TopoTarget Announces New Preclinical Results with Belinostat to be presented at AACR Annual Meeting

TopoTarget A/S announced today that new preclinical data on belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, will be presented at the upcoming American Association for Cancer Research (AACR) 2007 Annual Meeting in Los Angeles, April 14-18, 2007. A total of five poster presentations on belinostat (PXD101) will be made during the conference.

Belinostat (PXD101), HDAC inhibitor for the treatment of cancer:

• “Activity of PXD101, an HDAC inhibitor, used alone or in combination with 5-FU in preclinical gastroesophageal studies,” (Abstract #691) during the conference’s HDAC Inhibitors I poster session on Sunday, April 15th in the Exhibit Hall on Poster Board #14
• “Gene expression screen in cell panel selected for varying sensitivity towards the Histone Deacetylase inhibitor (HDACi) PXD101 reveals potential predictors of HDACi sensitivity,” (Abstract #687) during the conference’s HDAC Inhibitors I poster session on Sunday, April 15th in the Exhibit Hall on Poster Board #10
• “The effect of the histone deacetylase inhibitor (HDACi) PXD101 on cell growth and expression of viral and host genes in hepatitis B virus (HBV)-carrying hepatocellular carcinoma (HCC) cell lines,” (Abstract #696) during the conference’s HDAC Inhibitors I poster session on Sunday, April 15th in the Exhibit Hall on Poster Board #19
• “The histone deacetylase (HDAC) inhibitor PXD101 suppresses bladder cancer cell growth both in-vitro and in-vivo,” (Abstract #2211) during the conference’s Mouse Models of Cancer 2: Therapeutic Approaches poster session on Monday, April 16th on Poster Board #9
• “The HDAC inhibitors romidepsin and PXD101 interact synergistically with Bortezomib in human chronic lymphocytic leukemia (CLL) cells in association with NF-κB inactivation,” (Abstract #1835) during the conference’s Targeted Agents and Other Novel Therapies poster session on Monday, April 16th on Poster Board #21